» Articles » PMID: 31405037

Regulation of KIR3DL3 Expression Via Mirna

Overview
Journal Genes (Basel)
Publisher MDPI
Date 2019 Aug 14
PMID 31405037
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Killer-cell immunoglobulin-like receptor (KIR) 3DL3 is a framework gene present in all human KIR haplotypes. Although the structure of KIR3DL3 is suggestive of an inhibitory receptor, the function of KIR3DL3 has not been demonstrated and cognate ligands have not been identified. KIR3DL3 has been shown to be constitutively expressed at a low RNA level in peripheral blood mononuclear cell (PBMC) and decidual natural kill (NK) cells, but cell surface expression of KIR3DL3 cannot be detected. Accordingly, post-transcriptional regulation of KIR3DL3 should exist. Using bioinformatics analysis, we identified three candidate micro ribonucleic acids (miRNAs; miR-26a-5p, -26b-5p and -185-5p) that potentially regulate KIR3DL3 expression. Luciferase reporter assays utilizing constructs with mutated miRNA-binding sites of miR-26a-5p, -26b-5p and -185-5p in the 3'-untranslated region (3' UTR) of KIR3DL3 resulted in up-regulation of luciferase activity demonstrating a potential mechanism of gene regulation. Furthermore, knockdown of the same endogenous miRNAs using silencing ribonucleic acid (siRNA) led to induced surface expression of KIR3DL3. In conclusion, we provide a novel mechanism of functional regulation of KIR3DL3 via miRNAs. These findings are relevant in understanding the generation of KIR repertoire and NK cell clonality.

Citing Articles

The epigenetic hallmarks of immune cells in cancer.

Ji Y, Xiao C, Fan T, Deng Z, Wang D, Cai W Mol Cancer. 2025; 24(1):66.

PMID: 40038722 PMC: 11881328. DOI: 10.1186/s12943-025-02255-4.


The Importance of HHLA2 in Solid Tumors-A Review of the Literature.

Kula A, Koszewska D, Kot A, Dawidowicz M, Mielcarska S, Waniczek D Cells. 2024; 13(10.

PMID: 38786018 PMC: 11119147. DOI: 10.3390/cells13100794.


Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies.

Pulanco M, Madsen A, Tanwar A, Corrigan D, Zang X Cell Mol Immunol. 2023; 20(7):694-713.

PMID: 37069229 PMC: 10310771. DOI: 10.1038/s41423-023-01019-8.


KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy.

Li Y, Lv C, Yu Y, Wu B, Zhang Y, Lang Q J Adv Res. 2022; 47:137-150.

PMID: 35933091 PMC: 10173190. DOI: 10.1016/j.jare.2022.07.013.


Clinical Impact of KIR2DS3 and KIR2DL3 Genes in Neuroblastoma Patients.

Sezgin G, Ozturk O, Ozkan A, Kupeli S, Bayram I Med Princ Pract. 2022; 31(6):532-539.

PMID: 35537400 PMC: 9841757. DOI: 10.1159/000524656.


References
1.
Rajagopalan S, Long E . A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med. 1999; 189(7):1093-100. PMC: 2193010. DOI: 10.1084/jem.189.7.1093. View

2.
Wilson M, Torkar M, Haude A, Milne S, Jones T, Sheer D . Plasticity in the organization and sequences of human KIR/ILT gene families. Proc Natl Acad Sci U S A. 2000; 97(9):4778-83. PMC: 18309. DOI: 10.1073/pnas.080588597. View

3.
Vilches C, Rajalingam R, Uhrberg M, Gardiner C, Young N, Parham P . KIR2DL5, a novel killer-cell receptor with a D0-D2 configuration of Ig-like domains. J Immunol. 2000; 164(11):5797-804. DOI: 10.4049/jimmunol.164.11.5797. View

4.
Long E, Barber D, Burshtyn D, Faure M, Peterson M, Rajagopalan S . Inhibition of natural killer cell activation signals by killer cell immunoglobulin-like receptors (CD158). Immunol Rev. 2001; 181:223-33. DOI: 10.1034/j.1600-065x.2001.1810119.x. View

5.
Vilches C, Parham P . KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol. 2002; 20:217-51. DOI: 10.1146/annurev.immunol.20.092501.134942. View